Tiziana Life Sciences Ltd (NASDAQ:TLSA) said its investigational therapeutic foralumab will be highlighted by its scientific advisory board chairman Dr. Howard Weiner during an oral presentation at the 16th International Society of Neuroimmunology Congress in Quebec City, Canada.
The presentation, “Nasal anti-CD3 mAb induces Tregs that dampen microglial activation and treat neuroinflammatory diseases including MS, AD and ALS,” will take place at 11.42am Eastern Time on August 24, 2023.
“Dr. Weiner’s presentation on foralumab, or nasal anti-CD3 mAb will also include updates on our Multiple Sclerosis Expanded Access (EA) program,” Tiziana interim CEO Gabriele Cerrone commented.
Cerrone noted the company’s rapid progress with its foralumab program.
“This quarter, we have successfully filed our Alzheimer’s Investigational New Drug (IND) and received a 'may proceed' FDA response,” Cerrone said in a statement.
“In addition, we will conduct our multiple sclerosis Phase 2a investigator’s meeting, announce our 6-month clinical findings and PET scans for EA Patients 3 through 6 and lastly enroll EA patients 7 through 10.”
Dr. Weiner added: "We are expanding our understanding of foralumab through rigorous research and clinical trials designed to study this potential treatment for neuroinflammatory diseases.”
Meanwhile, the company announced that it has appointed Dr. William Clementi as its chief development officer (CDO), effective September 1, 2023.
As CDO, Dr. Clementi will oversee the company’s development strategies and advance its portfolio of groundbreaking therapeutic candidates.
Tiziana said he brings to the company a wealth of experience in the biopharmaceutical industry and has a track record of successfully guiding development programs from early stages through clinical trials, regulatory approval, and commercialization.
“I am excited to apply my regulatory and drug development experience and skills to Tiziana and contribute to the leadership team,” Dr. Clementi said in a statement.
“The company's commitment to addressing unmet medical needs and its dedication to scientific excellence are truly inspiring. I look forward to working closely with the talented team at Tiziana to drive the development of novel treatments that have the potential to make a meaningful impact on patients' lives.”
Tiziana interim CEO Cerrone added: "We are delighted to welcome William to Tiziana as our chief development officer. His extensive experience and leadership in drug development align perfectly with our company's vision to bring transformative therapies to patients in need.”
Tiziana Life Sciences is a clinical-stage biopharmaceutical company developing breakthrough therapies using transformational drug delivery technologies to enable alternative routes of immunotherapy.
- Updated with chief development officer appointment -
Contact the author at emily.jarvie@proactiveinvestors.com
Follow her on Twitter @emilyjjarvie